Human E-Cadherin ELISA Kit (ab233611)
Key features and details
- One-wash 90 minute protocol
- Sensitivity: 78 pg/ml
- Range: 156 pg/ml - 10000 pg/ml
- Sample type: Cell culture media, Cit plasma, EDTA Plasma, Hep Plasma, Saliva, Serum, Urine
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
Product nameHuman E-Cadherin ELISA Kit
See all E Cadherin kits
Intra-assay Sample n Mean SD CV% MCF-7 5 7.6% Inter-assay Sample n Mean SD CV% MCF-7 3 7.6%
Sample typeSaliva, Urine, Serum, Cell culture media, Hep Plasma, EDTA Plasma, Cit plasma
Assay typeSandwich (quantitative)
Range156 pg/ml - 10000 pg/ml
Sample specific recovery Sample type Average % Range Saliva 93 90% - 96% Urine 105 104% - 107% Serum 97 92% - 104% Cell culture media 100 98% - 103% Hep Plasma 103 92% - 109% EDTA Plasma 108 106% - 111% Cit plasma 97 93% - 98%
Assay time1h 30m
Assay durationOne step assay
Species reactivityReacts with: Human
Does not react with: Cow
Human E-Cadherin ELISA Kit (ab233611) is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of E-Cadherin protein in cit plasma, edta plasma, hep plasma, saliva, serum, urine, and cell culture media. It uses our proprietary SimpleStep ELISA® technology. Quantitate Human E-Cadherin with 78 pg/ml sensitivity.
SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:
- Single-wash protocol reduces assay time to 90 minutes or less
- High sensitivity, specificity and reproducibility from superior antibodies
- Fully validated in biological samples
- 96-wells plate breakable into 12 x 8 wells strips
A 384-well SimpleStep ELISA® microplate (ab203359) is available to use as an alternative to the 96-well microplate provided with SimpleStep ELISA® kits.
PlatformPre-coated microplate (12 x 8 well strips)
Storage instructionsStore at +4°C. Please refer to protocols.
Components 1 x 96 tests 10X Human E-Cadherin Capture Antibody 1 x 600µl 10X Human E-Cadherin Detector Antibody 1 x 600µl 10X Wash Buffer PT (ab206977) 1 x 20ml Antibody Diluent 4BI 1 x 6ml Human E-Cadherin Lyophilized Recombinant Protein 2 vials Plate Seals 1 unit Sample Diluent NS (ab193972) 1 x 50ml SimpleStep Pre-Coated 96-Well Microplate (ab206978) 1 unit Stop Solution 1 x 12ml TMB Development Solution 1 x 12ml
FunctionCadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells. Has a potent invasive suppressor role. It is a ligand for integrin alpha-E/beta-7.
E-Cad/CTF2 promotes non-amyloidogenic degradation of Abeta precursors. Has a strong inhibitory effect on APP C99 and C83 production.
Tissue specificityNon-neural epithelial tissues.
Involvement in diseaseDefects in CDH1 are the cause of hereditary diffuse gastric cancer (HDGC) [MIM:137215]. An autosomal dominant cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. Note=Heterozygous germline mutations CDH1 are responsible for familial cases of diffuse gastric cancer. Somatic mutations in the has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.
Defects in CDH1 are a cause of susceptibility to endometrial cancer (ENDMC) [MIM:608089].
Defects in CDH1 are a cause of susceptibility to ovarian cancer (OC) [MIM:167000]. Ovarian cancer common malignancy originating from ovarian tissue. Although many histologic types of ovarian neoplasms have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.
Sequence similaritiesContains 5 cadherin domains.
modificationsDuring apoptosis or with calcium influx, cleaved by a membrane-bound metalloproteinase (ADAM10), PS1/gamma-secretase and caspase-3 to produce fragments of about 38 kDa (E-CAD/CTF1), 33 kDa (E-CAD/CTF2) and 29 kDa (E-CAD/CTF3), respectively. Processing by the metalloproteinase, induced by calcium influx, causes disruption of cell-cell adhesion and the subsequent release of beta-catenin into the cytoplasm. The residual membrane-tethered cleavage product is rapidly degraded via an intracellular proteolytic pathway. Cleavage by caspase-3 releases the cytoplasmic tail resulting in disintegration of the actin microfilament system. The gamma-secretase-mediated cleavage promotes disassembly of adherens junctions.
Cellular localizationCell junction. Cell membrane. Endosome. Golgi apparatus > trans-Golgi network. Colocalizes with DLGAP5 at sites of cell-cell contact in intestinal epithelial cells. Anchored to actin microfilaments through association with alpha-, beta- and gamma-catenin. Sequential proteolysis induced by apoptosis or calcium influx, results in translocation from sites of cell-cell contact to the cytoplasm. Colocalizes with RAB11A endosomes during its transport from the Golgi apparatus to the plasma membrane.
- Information by UniProt
- Arc 1
- Cadherin 1
- Entrez Gene: 999 Human
- Omim: 192090 Human
- SwissProt: P12830 Human
- Unigene: 461086 Human
SimpleStep ELISA technology allows the formation of the antibody-antigen complex in one single step, reducing assay time to 90 minutes. Add samples or standards and antibody mix to wells all at once, incubate, wash, and add your final substrate. See protocol for a detailed step-by-step guide.
Standard curve comparison between Human E-Cadherin SimpleStep ELISA® kit and traditional ELISA kit from leading competitor. SimpleStep ELISA kit shows increased sensitivity.
The E-Cadherin standard curve was prepared as described in Section 10. Raw data values are shown in the table. Background-subtracted data values (mean +/- SD) are graphed.
The concentrations of E-Cadherin were measured in duplicates, interpolated from the E-Cadherin standard curves and corrected for sample dilution. Undiluted samples are as follows: serum 25%, plasma (EDTA) 12%, plasma (citrate) 12%, and plasma (heparin) 12%. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean E-Cadherin concentration was determined to be 47 ng/mL in serum, 36 ng/mL in plasma (EDTA), and 38 ng/mL plasma (heparin) and 34 ng/mL in plasma (citrate).
Interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean E-Cadherin concentration was determined to be 52 ng/mL with a range of 10 – 84 ng/mL.
The concentrations of E-Cadherin were measured in duplicate and interpolated from the E-Cadherin standard curve and corrected for sample dilution. Undiluted samples are as follows: MCF-7 cell culture supernatant 100% and urine 1.25%. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean E-Cadherin concentration was determined to be 1.9 ng/mL in MCF-7 supernatant and 45 ng/mL in urine.
The concentrations of E-Cadherin were measured in duplicate and interpolated from the E-Cadherin standard curve and corrected for sample dilution. Undiluted samples are as follows: saliva 6.25%. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean E-Cadherin concentration was determined to be 5 ng/mL in saliva.
To learn more about the advantages of recombinant antibodies see here.
Datasheets and documents
ab233611 has been referenced in 11 publications.
- Han YL et al. COL5A2 Inhibits the TGF-β and Wnt/β-Catenin Signaling Pathways to Inhibit the Invasion and Metastasis of Osteosarcoma. Front Oncol 12:813809 (2022). PubMed: 35280775
- Pawar K & Aranha C Lactobacilli metabolites restore E-cadherin and suppress MMP9 in cervical cancer cells. Curr Res Toxicol 3:100088 (2022). PubMed: 36176311
- Lei H et al. Baicalein modulates the radiosensitivity of cervical cancer cells in vitro via miR-183 and the JAK2/STAT3 signaling pathway. Adv Clin Exp Med 30:727-736 (2021). PubMed: 34118143
- Radwan AF et al. Association of MALAT1 and PVT1 Variants, Expression Profiles and Target miRNA-101 and miRNA-186 with Colorectal Cancer: Correlation with Epithelial-Mesenchymal Transition. Int J Mol Sci 22:N/A (2021). PubMed: 34200314
- Yang Y et al. E2F1-Induced lncRNA BAIAP2-AS1 Overexpression Contributes to the Malignant Progression of Hepatocellular Carcinoma via miR-361-3p/SOX4 Axis. Dis Markers 2021:6256369 (2021). PubMed: 34616498